FDA vet — and Wood­cock neme­sis — John Jenk­ins is step­ping over to a new role as a board mem­ber at Cor­bus Phar­ma

Af­ter mak­ing head­lines for his part in the FDA’s painful rup­ture over Sarep­ta’s Duchenne ap­proval, news of John Jenk­ins has been rather slow. But now, the for­mer head of the agency’s Of­fice of New Drugs is step­ping out to join the board of a small com­pa­ny just out­side Boston.

Jenk­ins — who spent about 15 years work­ing as the di­rec­tor of OND, over­see­ing the re­view of thou­sands of drug ap­pli­ca­tions — is quite the catch for Cor­bus Phar­ma­ceu­ti­cals. With his ex­ten­sive reg­u­la­to­ry back­ground, it makes sense for com­pa­nies to be seek­ing his in­sight on their boards. But Cor­bus is the first com­pa­ny board Jenk­ins agreed to sit on since leav­ing the FDA in 2017.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.